Pavmed raises $7m in private placement

Pavmed (NSDQ:PAVM) said this week that it inked a deal to sell a senior secured convertible note of $7.8 million to an institutional investor. The note was sold with an issue discount of $725,000, for gross proceeds to Pavmed of $7 million. Maxim Group, which acted as the placement agent for the transaction, received a 6.5% fee, according to a report filed with the SEC. The company said that after it consummated the sale of its convertible note, Pavmed repaid the outstanding principal balance and all accrued interest on a senior secured note held by an existing lender. Pavmed dealt a cash payment of $5 million to Scopia Holdings and issued 600,000 shares of common stock. Earlier this year, the FDA group reviewing the 510(k) application for Pavmed’s CarpX device said it wanted the company to resubmit its application. The FDA told the company that it had not reached a consensus within the review period set by the agency’s rules. To extend the review process, the FDA recommended that Pavmed resubmit the application. In a filing with the SEC, Pavmed said it resubmitted the application in August. The company’s minimally-invasive CarpX device is designed to treat carpal tunnel syndrome. The device allows physicians to relieve compression of a patient’s median nerve without the use of an incision. The ultrasound-guided system features a balloon catheter with bipolar radio-frequency cutting electrodes, according to Pavmed. Once the device i...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Featured Funding Roundup Wall Street Beat Pavmed Source Type: news

Related Links:

Authors: Teede HJ, Misso ML, Boyle JA, Garad RM, McAllister V, Downes L, Gibson-Helm M, Hart RJ, Rombauts L, Moran L, Dokras A, Laven J, Piltonen T, Rodgers RJ, Thondan M, Costello MF, Norman RJ, International PCOS Network Abstract INTRODUCTION: We have developed the first international evidence-based guideline for the diagnosis and management of polycystic ovary syndrome (PCOS), with an integrated translation program incorporating resources for health professionals and consumers. The development process involved an extensive Australian-led international and multidisciplinary collaboration of health professionals a...
Source: Medical Journal of Australia - Category: General Medicine Tags: Med J Aust Source Type: research
Publication date: 1 September 2019Source: Colloids and Surfaces B: Biointerfaces, Volume 181Author(s): Marina V. Novoselova, Denis V. Voronin, Tatiana O. Abakumova, Polina A. Demina, Arsenii V. Petrov, Vladimir V. Petrov, Timofei S. Zatsepin, Gleb B. Sukhorukov, Dmitry A. GorinAbstractHigh intensity focused ultrasound (HIFU) is widely used in medical practice, including cancer therapy. Also this approach is promising for remote release of encapsulated drugs in various other biomedical applications where local treatment is needed. Our approach underpins the minimization of HIFU impact on possible degradation of biological t...
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research
ConclusionAcute organophosphate poisoning treated with atropine showed a potential for inducing prothrombotic coagulation abnormalities, presented with PT. This life-threatening complication may additionally contribute to prolonged morbidity and mortality in OP poisonings, especially in patients with medical history of comorbidites.
Source: Toxicology Reports - Category: Toxicology Source Type: research
Publication date: September 2019Source: Urology Case Reports, Volume 26Author(s): Eriawan Agung Nugroho, Dila Junita, Yanuar Hendra WijayaAbstractGiant bladder stone more than 100 g is a rare finding and commonly associated with urinary tract infection. 32-year-old male came with history of lower abdominal pain, dysuria for 2 years. Patient had history of recurrence urinary tract infections for past 1 year and also complaint pollakiuria, incomplete emptying and hematuria. Abdominal radiograph and ultrasound revealed round calcified pelvic calculi. Patient received antibiotic and underwent open cystolithotomy. Extirpated ...
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
The FDA group reviewing the 510(k) application for Pavmed‘s (NSDQ:PAVM) CarpX device wants the company to resubmit the application. The FDA told the company that it had not reached a consensus within the review period set by the agency’s rules. To extend the review process, the FDA recommended that Pavmed resubmit the application. In a filing with the SEC, Pavmed said it initiated the submission this week and hopes to land a pre-submission meeting in the next 45 days. The company’s minimally-invasive CarpX device is designed to treat carpal tunnel syndrome. The device enables a physician to relieve c...
Source: Mass Device - Category: Medical Devices Authors: Tags: 510(k) Food & Drug Administration (FDA) Pain Management Regulatory/Compliance Pavmed Source Type: news
Within 24 hours of her second daughter’s birth, Dyane Harwood felt elated. From the moment she came home from the hospital, she started writing. Furiously. She wrote while nursing her daughter and going to the bathroom. She wrote on her hands, on the bathroom mirror, inside books and on tabletops. She yearned to write down every thought she was having. She wrote so much that her wrists ached—her carpal tunnel returning—and she was in constant pain. She also had endless energy and a newfound enthusiasm for life. She felt like she could run a long race. She couldn’t sit still, and her speech was fast ...
Source: World of Psychology - Category: Psychiatry & Psychology Authors: Tags: Bipolar Disorders General Health-related Mental Health and Wellness Self-Help Sleep Women's Issues Johns mood disorder Motherhood Parenting postpartum bipolar disorder postpartum depression Postpartum Disorder Source Type: blogs
Pavmed (NSDQ:PAVM) has registered for a nearly $90 million offering, saying it plans to float the rights to buy up to 14.6 million units. The New York City-based company said it would issue a single unit for each share of common stock. Each unit is slated to include one common share and a six-year Series Z warrant worth $2.25 per share, redeemable at $3 apiece. Pavmed plans to use the funds it raises from the offering to support its R&D efforts and the development of its current pipeline, according to the prospectus filed with the SEC. Last week, Pavmed cut the exercise price on the Series W w...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Funding Roundup Wall Street Beat Pavmed Source Type: news
Pavmed (NSDQ:PAVM) said today that it set the terms for a forthcoming rights offering, saying it plans to issue a single unit for each share of common stock. Each unit will include one common share and a six-year Series Z warrant worth $2.25 per share, redeemable at $3 each, the New York City-based company said. Last week, Pavmed cut the exercise price on the Series W warrants, from $2.50 to $2.00 apiece, its second price cut since late last year. Originally exercisable at $5.00 apiece, the company slashed the price in half last December. “Pavmed is providing this opportunity to exercise warrants ...
Source: Mass Device - Category: Medical Devices Authors: Tags: Funding Roundup Wall Street Beat Pavmed Source Type: news
Pavmed (NSDQ:PAVM) said today it would cut the cash exercise price of each of its Series W warrants from $2.50 to $2.00 apiece. This is the second price cut that Pavmed has given for its outstanding warrants. Each of the New York-based company’s outstanding warrants were exercisable at $5.00 apiece for one share of common stock before the company slashed the price in half in December. Pavmed also said today that it plans to implement a rights offering for holders of its common stock. The company will grant one transferable right to buy a new unit of Pavmed securities for each share of outstanding common sto...
Source: Mass Device - Category: Medical Devices Authors: Tags: Funding Roundup Wall Street Beat Pavmed Source Type: news
Pavmed (NSDQ:PAVM) said this week that it plans to temporarily cut the exercise price of its outstanding Series W warrants in half. Each of the New York-based company’s outstanding warrants is currently exercisable at $5.00 apiece for one share of common stock. After Pavmed files tender offer materials, each warrant will have an exercise price of $2.50 per share. The company said it expects the offer will be good for 20 business days, but it could decide to extend the deal. “Pavmed is providing this opportunity to exercise warrants at a reduced price in order to encourage holders to exercise a meaningful p...
Source: Mass Device - Category: Medical Devices Authors: Tags: Funding Roundup Pain Management Wall Street Beat Pavmed Source Type: news
More News: Bipolar | Carpal Tunnel Syndrome | Funding | Mania | Medical Devices | Ultrasound